LEVEL OF TRANSFORMING GROWTH FACTOR BETA-1 RELATES TO CONGENITAL LIVER DISEASE SEVERITY IN CHILDREN OF EARLY AGE

Aim. Analysis of relationship between transforming growth factor beta-1 (TGF-β1) level in blood and liver disease severity before and after liver transplantation in early age children with congenital liver diseases. Materials and methods. The study included 135 pediatric patients aged from 2 to 73 months with end-stage liver disease. Results. The level of TGF-β1 in the blood of children with liver failure on average was lower than in healthy children of the same age. The cytokine level depended on the liver disease etiology: in patients with biliary atresia, biliary hypoplasia, Alagille syndrome, Byler disease and other diseases it was lower than that at Caroli disease when it did not differ from the level in healthy children. The level of cytokine in the blood plasma of patients was associated with the severity of hepatic fi brosis: in fi brosis of grade 1 and 4 it was lower than in fi brosis of grade 2 and 3. The liver transplantation from related living donor resulted in increase of TGF-β1 level in the blood plasma of patients regardless of the initial etiology and severity of the liver disease. Conclusion. The blood level of TGF-β1 refl ects liver disease severity in children with congenital liver diseases and may be used as a marker of liver function state before and after liver transplantation. 

1. Готье СВ. Трансплантология: итоги и перспективы. Том VI. 2014 год. М.–Тверь: Триада, 2015. 448. Gautier SV: Transplantologiya: itogi i perspectivy. Tom VI. 2014 god. M.–Tver: Triada, 2015. 448. [In Russian]

2. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 2000; 342 (18): 1350–1358.

3. Charles R, Chou HS, Wang L, Fung JJ, Lu L, Qian S. Hu￾man hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation. 2013; 96 (1): 17–24.

4. Annoni G, W einer FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. J. Hepatol. 1992; 14 (2–3): 259–264.

5. Kanzler S, Ba umann M, Schirmacher P, Dries V, Bayer E, Gerken G et al. Prediction of progressive liver fi - brosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J. Viral. Hepat. 2001; 8 (6): 430–437.

6. Rosensweig JN, Omori M, Page K, Potter CJ, Perlman EJ, Thorgeirsson SS et al. Transforming growth factor-beta1 in plasma and liver of children with liver disease. Pediatr. Res. 1998; 44 (3): 402–409.

7. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev. Immunol. 2006; 24: 99–146.

8. Li W, Kuhr CS, Z heng XX, Carper K, Thomson AW, Reyes JD et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am. J. Transplant. 2008; 8 (8): 1639–1651.

9. Nakano T, Lai CY, Goto S, Hsu LW, Kawamoto S, Ono K et al. Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance. PloS one. 2012; 7 (5): 15.

10. Briem-Richter A, Leuschner A, Krieger T, Grabhorn E, Fischer L, Nashan B et al. Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation. Pediatr. Transplant. 2013; 17 (8): 757–764.

11. Шевченко ОП, Цирульникова ОМ, Курабекова РМ, Цирульникова ИЕ, Олефиренко ГА, Готье СВ. Уровень трансформирующего фактора роста β1 в плазме крови детей – реципиентов печени и его связь с функцией трансплантата. Иммунология. 2015; 36 (6): 343–347. Shevchenko OP, Tsirulnikova OM, Kurabekova RM, Tsirulnikova IE, Olefi renko GA, Gautier SV. Blood plasma level of transforming growth factor β1 in pediatric liver transplant recipients and its relationship with graft function. Immunologiya. 2015; 36 (6): 343– 347. [In Russian (abstract in English)]

12. Hussein MH, Hashimo to T, AbdEl-Hamid Daoud G, Kato T, Hibi M, Tomishige H et al. Pediatric patients receiving AB0-incompatible living related liver transplantation exhibit higher serum transforming growth factor-beta1, interferon-gamma and interleukin-2 levels. Pediatr. Surg. Int. 2011; 27 (3): 263–268.

13. Hussein MH, Hashimot o T, Suzuki T, Daoud GA, Goto T, Nakajima Y et al. Children undergoing liver transplantation for treatment of inherited metabolic diseases are prone to higher oxidative stress, complement activity and transforming growth factor-beta1. Ann. Transplant. 2013; 18: 63–68.

14. Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC et al. The role of serum biomarkers in predicting fi brosis progression in pediatric and adult hepatitis C virus chronic infection. PloS ONE. 2011; 6 (8): e23218. doi: 10.1371/journal.pone.0023218.